Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.
On October 28, the Community Oncology Alliance (COA) hosted a summit on oncology payment reform which featured a panel entitled “Biosimilar Opportunities, Challenges, and Realities.” Panelist Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana and member of the board of directors for COA, discussed some of the current challenges and barriers to uptake for biosimilars. Excerpts from that panel discussion are included here.
To learn more about the COA's virtual Payer Exchange Summit on Oncology Payment Reform, click here.
To learn more about Pontchartrain Cancer Center, click here.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.